Sylvester Comprehensive Cancer Center

Shaun Brothers, Ph.D.

Shaun Brothers, Ph.D.

Assistant Professor of Psychiatry

Description of Research

Dr. Brothers’ research focus is on drug discovery. Dr. Brothers is trained as a pharmacologist and expert in drug discovery and development. In his graduate work, he identified the mode of action of a pharmacological chaperone for the gonadotropin-releasing hormone receptor, a G protein coupled receptor. Dr. Brothers pursued further work in developing novel therapeutics and sought postdoctoral training in drug discovery. The Scripps Research Institute had started a Florida Campus dedicated to the discovery and development of novel therapeutics. Dr. Brothers was among the first to join Scripps Florida in 2006 and initiated several new drug discovery projects including several that utilized the high throughput screening capabilities available at Scripps. After Scripps Florida, Dr. Brothers was recruited to the University of Miami as an Assistant Professor in the Department of Psychiatry and Behavioral Sciences. Dr. Brothers also co-founded the Center for Therapeutic Innovation at the Miller School. Dr. Brothers has embarked on a number of successful compound discovery efforts including several aimed at cancer targets. Dr. Brothers works daily with medicinal chemists, pharmacologists, screeners, engineers, drug metabolism experts, behaviorists and other experts to advance compounds. One such compound is currently being utilized by the research community (SF-11, sold by Tocris). In another notable project, Dr. Brothers has worked to develop novel BRD4 inhibitors. Such compounds could be useful for the treatment of a number of different cancers including glioblastoma multiforme (GBM). These compounds have been licensed out into a spin out company working to develop the compounds for GBM. Dr. Brothers’ current work also includes the identification of novel HIF2alpha inhibitors for use in research relating to cancer via an ultra-high throughput screening effort being conducted in collaboration with the Sanford-Burnham Institute.

Highlights

  • Discovered the mechanism of action for pharmacological chaperones.
  • Discovered several novel chemotypes for disease-oriented targets by high throughput screening efforts.
  • Developed novel inhibitors for bromodomain containing proteins such as BRD2/3/4.
  • Identified a novel pathway in PTSD by use of novel compounds developed in the lab.
  • Identified a potential novel therapy for mucopolysaccharidosis I.
  • Developed the first ever selective nociceptin receptor agonists.
  • Identified novel epigenetic pathways in disease.
  • Selected Cancer-Related Publications

E-mail a Friend